ReviewFrontiers in immunology2022
C-reactive protein, immunothrombosis and venous thromboembolism.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 2 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- The value of platelet-associated parameters as biomarkers in evaluating the disease activity of inflammatory bowel disease: a systematic review and meta-analysis.BMC gastroenterology · 2026Pooled it
- Prognostic value of the CALLY index for functional outcomes in acute ischemic stroke: a systematic review and exploratory quantitative synthesis.Frontiers in neurology · 2026Pooled it
- Inflammation-coagulation biomarkers predict catheter-related thrombosis following peripherally inserted central catheter placement in patients with hematologic malignancies: a retrospective cohort study.Translational cancer research · 2026Article
- Malignancy as a Predictor and Potential Modifier of Laboratory Biomarker Prognostic Value in Acute Pulmonary Embolism.Diagnostics (Basel, Switzerland) · 2026Article
- Association between the albumin-to-globulin ratio and deep vein thrombosis in older adults receiving home healthcare: a prospective cohort study.Irish journal of medical science · 2026Article
- The MCP-1/CCR2-CD16⁺ monocyte axis drives thrombus fibrosis in Chronic Thromboembolic Pulmonary Hypertension.Journal of translational medicine · 2026Article
- Associations Between Metabolic Score for Visceral Fat and Venous Thromboembolism Among 118 619 Participants With Metabolic Syndrome: Insights From Epidemiology to Genetic Susceptibility.Journal of the American Heart Association · 2026Article
- Association of triglyceride-glucose related indices with the incidence of venous thromboembolism: a nationwide prospective cohort study based on the UK Biobank.BMC cardiovascular disorders · 2026Article
- In-Stent Restenosis Pathophysiology and Risk Factors: A Comprehensive Review.Medicina (Kaunas, Lithuania) · 2026Review
- Exploring blood transcriptional signatures for thrombosis diagnosis in critically ill patients with COVID-19.Blood vessels, thrombosis & hemostasis · 2026Article
- Characteristics of Cancer-Associated Thrombosis Based on Changes in Clinically Measurable Coagulation Factors and Coagulation/Fibrinolysis Markers in Patients with Cancer: A Multicenter Cross-Sectional Study.Annals of vascular diseases · 2026Article
- Coagulation is associated with renal function decline and chronic kidney disease in people living with HIV in South Africa.Frontiers in nephrology · 2026Article
- Machine learning prediction of postoperative pulmonary embolism: a multicenter external validation study highlighting inflammatory response and intraoperative hemodynamics.Frontiers in cardiovascular medicine · 2026Article
- Machine learning-based prediction of in-hospital deep vein thrombosis in patients with acute ischemic stroke: a multicenter study.Frontiers in neurology · 2026Article
- Association between fibrinogen and decline in cardiorespiratory fitness in patients undergoing cardiopulmonary exercise testing: a large cross-sectional study.Frontiers in cardiovascular medicine · 2026Article
- β-Antithrombin Levels in Patients with Venous Thromboembolism.International journal of molecular sciences · 2025Article
- Inflammatory markers and clinical outcomes in acute/subacute severe cerebral venous thrombosis: the role of glucocorticoid therapy.BMC neurology · 2025Article
- Feasibility and clinical value of nurse-led point-of-care ultrasound screening for prethrombotic state in postoperative cardiac ICU patients: a cross-sectional study.The ultrasound journal · 2025Article
- Chronic Dyspnea and Residual Pulmonary Vascular Sequelae After COVID-19 Pulmonary Embolism: A Retrospective Analysis.Pulmonary circulation · 2025Article
- Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
C-reactive protein (CRP) is a member of the highly conserved pentraxin superfamily of proteins and is often used in clinical practice as a marker of infection and inflammation. There is now increasing evidence that CRP is not only a marker of inflammation, but also that destabilized isoforms of CRP possess pro-inflammatory and pro-thrombotic properties. CRP circulates as a functionally inert pentameric form (pCRP), which relaxes its conformation to pCRP* after binding to phosphocholine-enriched membranes and then dissociates to monomeric CRP (mCRP). with the latter two being destabilized isoforms possessing highly pro-inflammatory features. pCRP* and mCRP have significant biological effects in regulating many of the aspects central to pathogenesis of atherothrombosis and venous thromboembolism (VTE), by directly activating platelets and triggering the classical complement pathway. Importantly, it is now well appreciated that VTE is a consequence of thromboinflammation. Accordingly, acute VTE is known to be associated with classical inflammatory responses and elevations of CRP, and indeed VTE risk is elevated in conditions associated with inflammation, such as inflammatory bowel disease, COVID-19 and sepsis. Although the clinical data regarding the utility of CRP as a biomarker in predicting VTE remains modest, and in some cases conflicting, the clinical utility of CRP appears to be improved in subsets of the population such as in predicting VTE recurrence, in cancer-associated thrombosis and in those with COVID-19. Therefore, given the known biological function of CRP in amplifying inflammation and tissue damage, this raises the prospect that CRP may play a role in promoting VTE formation in the context of concurrent inflammation. However, further investigation is required to unravel whether CRP plays a direct role in the pathogenesis of VTE, the utility of which will be in developing novel prophylactic or therapeutic strategies to target thromboinflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.